20 This poor prognostic subtype is consistently defined in molecular classifications of PDAC (also termed Quasi-Mesenchymal 21 or Basal 22 ) and S100A2 remains a highly significant gene in each classifier. 20 – 22 Here, we assess and validate the prognostic value of these 2 molecules in 1184 patients.
← all excerpts
Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer.
1
—
—